Jennison Associates LLC Takes $20.25 Million Position in Repligen Corporation $RGEN

Jennison Associates LLC purchased a new stake in Repligen Corporation (NASDAQ:RGEN) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm purchased 123,600 shares of the biotechnology company’s stock, valued at approximately $20,253,000.

Other large investors have also made changes to their positions in the company. Measured Wealth Private Client Group LLC purchased a new position in shares of Repligen in the 3rd quarter valued at about $29,000. Bayforest Capital Ltd purchased a new position in shares of Repligen in the 4th quarter valued at about $32,000. Rachor Investment Advisory Services LLC purchased a new position in shares of Repligen in the 4th quarter valued at about $33,000. CWM LLC increased its holdings in shares of Repligen by 67.2% in the 3rd quarter. CWM LLC now owns 336 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 135 shares in the last quarter. Finally, Farther Finance Advisors LLC increased its holdings in shares of Repligen by 61.8% in the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 128 shares in the last quarter. Hedge funds and other institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

RGEN has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of Repligen from a “hold (c-)” rating to a “sell (d+)” rating in a report on Tuesday, March 3rd. UBS Group cut their price target on shares of Repligen from $200.00 to $195.00 and set a “buy” rating for the company in a report on Wednesday, February 25th. Roth Mkm initiated coverage on shares of Repligen in a research note on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective on the stock. HC Wainwright upped their price target on shares of Repligen from $180.00 to $208.00 and gave the company a “buy” rating in a report on Monday, March 23rd. Finally, Wells Fargo & Company reduced their price target on shares of Repligen from $190.00 to $180.00 and set an “overweight” rating on the stock in a report on Wednesday, February 25th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $170.25.

Repligen Trading Down 0.9%

Shares of RGEN opened at $117.20 on Friday. The company has a debt-to-equity ratio of 0.26, a current ratio of 8.37 and a quick ratio of 7.12. The firm has a 50 day simple moving average of $121.56 and a 200-day simple moving average of $144.70. Repligen Corporation has a 1-year low of $109.50 and a 1-year high of $175.77. The stock has a market cap of $6.61 billion, a price-to-earnings ratio of 137.88, a price-to-earnings-growth ratio of 2.28 and a beta of 1.09.

Repligen (NASDAQ:RGEN) last issued its quarterly earnings data on Tuesday, February 24th. The biotechnology company reported $0.49 earnings per share for the quarter, topping analysts’ consensus estimates of $0.44 by $0.05. Repligen had a net margin of 6.62% and a return on equity of 4.71%. The business had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same period last year, the company posted $0.44 EPS. The company’s revenue was up 18.1% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. Equities analysts forecast that Repligen Corporation will post 1.97 EPS for the current fiscal year.

About Repligen

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.